Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK7 | P49862 | 3/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | MIF | P14174 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9265342 | 0.98 | KLK7 (0.60) | KLK7L3MBTL1TDP1ALDH1A1MAPK1 | |
| SCHEMBL7495579 | 0.95 | KLK7 (0.57) | KLK7L3MBTL1TDP1ALDH1A1MAPK1 | |
| SCHEMBL2232191 | 0.92 | ALDH1A1 (0.56) | KLK7L3MBTL1TDP1ALDH1A1MAPK1 | |
| SCHEMBL16417273 | 0.89 | KLK7 (0.51) | KLK7L3MBTL1TDP1ALDH1A1MAPK1 | |
| SCHEMBL29307410 | 0.87 | ALDH1A1 (0.50) | KLK7L3MBTL1TDP1ALDH1A1MAPK1 | |
| SCHEMBL20023110 | 0.85 | MEN1 (0.50) | KLK7TDP1ALDH1A1MAPK1MEN1 | |
| SCHEMBL7060349 | 0.85 | ITGB3 (0.49) | KLK7L3MBTL1ALDH1A1MAPK1 | |
| SCHEMBL31061934 | 0.85 | ALDH1A1 (0.49) | KLK7L3MBTL1ALDH1A1MAPK1MEN1 | |
| SCHEMBL304920 | 0.84 | NPC1 (0.55) | L3MBTL1TDP1ALDH1A1MAPK1MEN1 | |
| SCHEMBL31226906 | 0.84 | KLK7 (0.50) | KLK7L3MBTL1TDP1ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1415986-B1 | SPIRO ISOBENZOFURANES AS NEUROPEPTIDE Y RECEPTOR ANTAGONISTS | BANYU PHARMA CO LTD (JP) | 2009-04-08 | — | — | EP | disclosed |
| US-7205417-B2 | Spiro compounds | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-04-17 | — | — | US | disclosed |
| US-20040259890-A1 | Spiro compounds | MSD K.K. (JP) | 2004-12-23 | — | — | US | disclosed |
| EP-1415986-A1 | SPIRO COMPOUNDS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2004-05-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259890-A1 | Spiro compounds | OPRD1, PER2, OPRK1 | KLK7 3657/4885L3MBTL1 1819/4885TDP1 3362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.